ID
26883
Description
Study ID: 101468/199 Clinical Study ID: 101468/199 Study Title: An open label study conducted in healthy volunteers to characterize the pharmacokinetics of a new unmarketed formulation of ropinirole Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 1 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Modutab,ZIPEREVE,ZEPREVE,REPREVE,ADARTREL,REQUIP,Zygara; Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL Study Indication: Restless Legs Syndrome Documentation part (Visit Description): Non-Serious Adverse Event
Keywords
Versions (1)
- 10/27/17 10/27/17 -
Copyright Holder
GlaxoSmithKline
Uploaded on
October 27, 2017
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Pharmacokinetics of a new unmarketed formulation of ropinirole Non-Serious Adverse Event 101468/199
Non-Serious Adverse Event
- StudyEvent: ODM
Similar models
Non-Serious Adverse Event
- StudyEvent: ODM
C0244821 (UMLS CUI-2)
C0011900 (UMLS CUI [1,2])
C0808070 (UMLS CUI [1,2])
C2697889 (UMLS CUI [1,2])
C1518404 (UMLS CUI [1,2])
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
C0806020 (UMLS CUI [1,2])
C1518404 (UMLS CUI [1,2])
C0439603 (UMLS CUI [1,2])
C1518404 (UMLS CUI [1,2])
(Comment:en)
(Comment:en)
(Comment:en)
C1518404 (UMLS CUI [1,2])
(Comment:en)
(Comment:en)
(Comment:en)
C0443172 (UMLS CUI-2)
(Comment:en)
C0178602 (UMLS CUI-2)
(Comment:en)
C1518404 (UMLS CUI [1,2])
C1518404 (UMLS CUI [1,2])